Amgen's SWOT analysis: stock poised for growth amid obesity drug potential
Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...
pharmaphorum9d
Amgen’s Enbrel heads ICER list of unjustified US price rises
US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019 ... US rate of inflation in that year. Amgen’s venerable TNF inhibitor Enbrel ...
Zacks.com on MSN2d
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...
Amgen’s Sell Rating: Declining EPS and Overvalued Stock Amid Modest Revenue Growth
In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...
pharmaphorum5y
CHMP says no to Amgen’s osteoporosis drug Evenity
The EMA’s Committee for Medicinal Products for Human Use (CHMP ... Prolia, a RANK inhibitor, is one of Amgen’s top-selling drugs with sales of $2.3 billion last year, but will start losing ...
Yahoo Finance18d
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Many investors also have a go-to methodology that helps guide their buy and sell decisions ... blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta.
Yahoo Finance18d
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.